SG11201908679QA - Isomerically pure 18f-labelled tetrahydrofolates - Google Patents

Isomerically pure 18f-labelled tetrahydrofolates

Info

Publication number
SG11201908679QA
SG11201908679QA SG11201908679QA SG11201908679QA SG 11201908679Q A SG11201908679Q A SG 11201908679QA SG 11201908679Q A SG11201908679Q A SG 11201908679QA SG 11201908679Q A SG11201908679Q A SG 11201908679QA
Authority
SG
Singapore
Prior art keywords
international
labelled
pct
isomerically pure
tetrahydrofolates
Prior art date
Application number
Inventor
Rudolf Moser
Viola Groehn
Cristina Mueller
Roger Schibli
Simon Ametamey
Silvan Boss
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201908679QA publication Critical patent/SG11201908679QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT omit VIII °nolo olo X111011101011 0 101111111 ow (10) International Publication Number WO 2018/172243 Al (51) International Patent Classification: CO7D 475/04 (2006.01) CO7B 59/00 (2006.01) A61K 31/519 (2006.01) (21) International Application Number: PCT/EP2018/056806 (22) International Filing Date: 19 March 2018 (19.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17161884.6 20 March 2017 (20.03.2017) EP (71) Applicant: MERCK PATENT GMBH [DE/DE]; Frank- furter Strasse 250, 64293 Darmstadt (DE). (72) Inventors: MOSER, Rudolf; Lahnhalde 11, 8200 SCHAFFHAUSEN (CH). GROEHN, Viola; Bahnhofs- trasse 2, 8447 DACHSEN (CH). MUELLER, Cristi- na; Haldenstrasse 24, 5415 NUSSBAUMEN (CH). SCHIBLI, Roger; Schartenrainstrasse 42, 8093 BADEN (CH). AMETAMEY, Simon; Uetlibergstrasse 308, 8045 ZUERICH (CH). BOSS, Silvan; Rosentrasse 1, 2562 PORT (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: ' 6 E-4 with international search report (Art. 21(3)) 71' N (54) Title: ISOMERICALLY PURE 18F-LABELLED TETRAHYDROFOLATES 1-1 (57) : The present invention is directed towards isomerically pure 18 F-labelled (6S)-or (6R)-5-methyltetrahydrofolate radio- pharmaceuticals, wherein the phenyl group within the folate structure, has been replaced by an F-labelled N-heterocycle, for use in 18 \" diagnostic imaging of a cell or population of cells expressing a folate-receptor in vitro or in vivo or for use in monitoring of cancer or 0 inflammatory and autoimmune diseases and therapy thereof.
SG11201908679Q 2017-03-20 2018-03-19 Isomerically pure 18f-labelled tetrahydrofolates SG11201908679QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17161884 2017-03-20
PCT/EP2018/056806 WO2018172243A1 (en) 2017-03-20 2018-03-19 Isomerically pure 18f-labelled tetrahydrofolates

Publications (1)

Publication Number Publication Date
SG11201908679QA true SG11201908679QA (en) 2019-10-30

Family

ID=58387756

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908679Q SG11201908679QA (en) 2017-03-20 2018-03-19 Isomerically pure 18f-labelled tetrahydrofolates

Country Status (16)

Country Link
US (1) US20200306390A1 (en)
EP (1) EP3601288B1 (en)
JP (1) JP7204662B2 (en)
KR (1) KR102648945B1 (en)
CN (1) CN110431141B (en)
AU (1) AU2018237784B2 (en)
CA (1) CA3057042A1 (en)
DK (1) DK3601288T3 (en)
EA (1) EA201992180A1 (en)
ES (1) ES2893303T3 (en)
IL (1) IL269059B (en)
PL (1) PL3601288T3 (en)
PT (1) PT3601288T (en)
SG (1) SG11201908679QA (en)
WO (1) WO2018172243A1 (en)
ZA (1) ZA201906877B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201901010T4 (en) 2007-04-11 2019-02-21 Merck & Cie 18F labeled folates.
SI2254890T1 (en) * 2008-02-20 2015-08-31 Gnosis S.P.A. Process for the diastereoisomeric resolution of 5-methyltetrahydrofolic acid
US20130034496A1 (en) * 2011-08-04 2013-02-07 University Of Iowa Research Foundation Positron emission tomography tracer
WO2013167653A1 (en) * 2012-05-08 2013-11-14 Merck & Cie 18f-labelled folate/antifolate analogues

Also Published As

Publication number Publication date
ES2893303T3 (en) 2022-02-08
CN110431141B (en) 2022-12-30
JP2020511477A (en) 2020-04-16
AU2018237784B2 (en) 2022-04-21
AU2018237784A1 (en) 2019-11-07
US20200306390A1 (en) 2020-10-01
CA3057042A1 (en) 2018-09-27
EA201992180A1 (en) 2020-04-23
KR102648945B1 (en) 2024-03-18
CN110431141A (en) 2019-11-08
JP7204662B2 (en) 2023-01-16
PT3601288T (en) 2021-07-20
WO2018172243A1 (en) 2018-09-27
IL269059B (en) 2021-12-01
EP3601288B1 (en) 2021-04-21
EP3601288A1 (en) 2020-02-05
DK3601288T3 (en) 2021-07-05
IL269059A (en) 2019-11-28
ZA201906877B (en) 2021-06-30
KR20190130607A (en) 2019-11-22
PL3601288T3 (en) 2021-11-08

Similar Documents

Publication Publication Date Title
SG11201805072PA (en) Nicotine powder delivery system
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201811640SA (en) Multispecific antigen binding proteins and methods of use thereof
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201811225RA (en) Ar+ breast cancer treatment methods
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201909501TA (en) Personalized 3d neural culture system for generating human oligodendrocytes and studying myelination in vitro
SG11201906041QA (en) Pharmaceutical compositions for combination therapy
SG11201806512VA (en) Copanlisib biomarkers
SG11201909064RA (en) Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion
SG11201900361RA (en) Methods of treating prostate cancer
SG11201900043TA (en) Antibody formulations
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201900336YA (en) Radioligands for imaging the ido1 enzyme
SG11201900132QA (en) Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
SG11201908513RA (en) Peptides for treatment of diabetes
SG11201907844TA (en) Novel spiro and cyclic bis-benzylidine proteasome inhibitor for the treatment of cancer, diabetes and neurological disorders